Company intelligence / Profile preview

Eleventa

Ownership: Private
Development stage: Commercial

Overview

Eleventa’s lead drug candidate, Timapiprant (formerly OC000459), is a highly potent and selective oral small molecule antagonist of the CRTH2 receptor. The company completed patient enrollment for a Phase 3 clinical trial in adults with atopic eosinophilic asthma. Timapiprant aims to reduce airway inflammation, improve asthma control, and decrease dependence on inhaled corticosteroids. The drug has shown persistent anti-allergic effects and desensitization potential without the side effects associated with glucocorticoid therapy.

Therapeutic areas: PulmonologyImmunology
Modalities: Small molecule
Industry: Biotech

Partnerships

Oxagen Limited (UK) – development partner for lead programSkolkovo Innovation Center – residency/affiliation

Beyond the preview

Go deeper on Eleventa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eleventa.

Explore the full profile